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Abstract. High Altitude Pulmonary Oedema (HAPO) is the most common serious 
ailment affecting troops serving at high altitude. The incidence is about 1 in 200 
amongst ~ndividuals proceeding by air to an altitude of 11 000 feet (3,413.7 m). 
The manifestations of HAPO are : cough, dyspnoea, haemoptysis, weakness, 
absence of signs of infection, presence of pulmonary rales and cyanosis and 
prompt disappearance of symptoms and signs with treatment with bed rest, and 
therapy with supplemental oxygen. Prompt and adequate treatment yields eminent- 
ly gratifying results in practically every instance. Oxygen and bed rest remain 
the sheet anchor of treatment, supplemented on occasion by diuretics and seda- 
tives. The role of digoxin in the therapy of HAPO is debateable and its aetio- 
pathogenesis is sti!l unclear. The paper presents the clinical data of the first 
series of cases to be reported from India, and compares the findings with those of 
other and subsequent workers. 
1. Introduction 
High Altitude Pulmonary Oedema (HAPO) is the most common serious illness affect- 
ing Indian troops, serving in mountainous areas1. Over the past 20 years more than 
2000 cases of this potentially life-threatening disorder have occurred in India. HAPO 
has also affected mountaineers in various parts of the world, and has aroused there- 
fore considerable interest in mountaineering circles. The disease is precipitated by 
rapid ascent to altitudes above 8,000 feet (2,400 m) and is seldom seen on slow ascent 
occurring over several days. The most frequent symptoms are breathlessness at rest, 
chest pain, cough, and expectoration of frothy and sometimes pink sputum. The 
common physical findings are cyanosis, tachypnoea, tachycardia, right ventricular 
heave and accentuated pulmonary second sound. Radiologically fluffy shadows are 
seen in both lung fields. Many deaths have been reported amongst mountaineers and 
also amongst troops. Descent to lower altitude or administration of oxygen at high 
rates of flow, generally results in improvement of the patient. 
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Historically, the disease was first described by Mosso in 1898. Hurtado reported 
the first case in South America while Houston2 w a ~  the first to record a case in English 
literature. Subsequently a few cases have been reported sporadically from various 
parts of the world. The disease really burst upon the world of medicine in almost 
epidemic proportions in 1962. Inder Singh3 et a1 and Menonl have reported a few 
hundred cases. The study of 101 cases of HAPO reported in the latter series was 
carried out at a hospital located at 11,200 feet (3,413.7 m). The aim of the present 
paper is to rz-evaluate these observations in the light of subsequent studies by workers 
in different parts of the world. 
2. Earlier Observations 
2.1 Observations by Menonl 
During the two-year period 1962-64, 101 cases of high altitude pulmonary oedema 
were diagnosed and treated at the field hospital at Leh, Ladakh in India. The incidence 
of the disease amongst troops arriving at high altitude by air was 5.7 per thousand. 
It was less common amongst arrivals by road. As would be expected, out of 66 
patients between June 63 and May 64, 49 patients were admitted during the six-month 
period December 63-May 64 when the roads were closed, as against only 17 admitted 
during June-November 1963 when arrival was by both road and air. Symptoms 
usually developed within 1-3 days of arrival. Although in 10 cases of HAPO, the 
people had subjected themselves to violent exertion immediately after arrival, the 
fact that 66 of the 101 patients were employed on sedentary duties, tended to diminish 
the 'significance of the stress of exertion on the precipitation of HAPO. 
Typically, the sequence of events was as follows : during the first three days of 
arrival the patient often had insomnia, headache, dizziness, nausea and palpitations; 
and would develop a dry cough, which was short, sharp and suppressed, and did not 
inconvenience him very much. As the condition advanced, breathlessness would 
increase and mucoid sputum would be expectorated. Frothy pink sputum, large in 
quantity, and thin in consistency would indicate the occurrence of pulmonary oedema 
in all its severity. Substernal discomfort leading on to a dull ache or pain was often 
present. An occasional patient was apathetic, or boisterously violent or lapsed 
insidiously into deep coma. 
The physical findings consisted of central cyanosis (521101 patients) and a rather 
low blood pressure. The pulmonary second sound was palpable and the cardiac 
impulse was of right ventricular pattern. The pulmonary findings were the most 
signifi~ant of all. From a prolongation and harshness of expiration in the right 
interscapular region as the earliest signs, fine crepitations soon appeared in both 
interscapular and infrascapular regions. Soon coarse crackling crepitations would 
appear throughout both lungs and bubbling rates would completely mask heart 
sounds. 
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X-ray of HAPO patients indicated woolly opacities in both lungs in the upper and 
middle zones (Figs. I & 2). Starting off as a fuzziness of the vascular shadows in the 
- 
Figure 1. Lung X-ray of  HAPO patient, (a) on admission, (b)  four days later. 
Figure 2. Lung X-ray of HAPO patient, (a) on admission, (b) four days later- 
320 N D Menon 
right middle zone, woolly shadows would spread throughout both lungs. The pulmo- 
- 
nary conus was prominent in some patients. Barium swallow examination in six 
patients taken during the acute phase and repeated after recovery showed some easing 
of the pressure on the barium filled oesophagus with recovery. The electrocardiogram 
was normal in most patients, but an occasional finding was raising of ST segment in 
praecordial leads, symmetrical T-Wave inversion and clock-wise rotation of the heart. 
An abnormal Q-Wave was never present. 
The disease in most patients responded very well to bed rest and oxygen therapy 
by intra-nasal catheter/BLB mask at rates of flow of 6-8 litreslmin at the hospital, locat- 
ed at 11,209 feet (3413.7 m). 34 of 101 patients (i.e. 34 per cent) recovered completely 
on oxygen alone. Improvement was apparent within 30 min to 120 min. Digoxin 
was administered to 66 patients in a dosage of 0.5 to 1.5 mg 1.V. Response to 
treatment was invariably good. In 24 of these patients digoxin was administered 
onlyafter two hours of oxygen had not improved the condition of the patient. 
In the remaining 42, digoxin was injected at the start of treatment. A small trial 
dose of digoxin 1.5-2 mg I. V. without supportive oxygen in six patients yielded 
equally good results. Diuretics (mersalyl or hydrochlorothiazide) was given to 48 
patients on admission, but this practice was discontinued in the latter part of the 
study, as no useful purpose seemed to be served. Morphia invariably improved the 
depth of respiration and decreased dyspnoea. 
There were four deaths altogether, all in the initial stages of the study (i.e. 
between cases 1 and 16) and no death occurred subsequently. 
On the basis of this study of 101 cases it was suggested that myocardial failure 
secoxidary to hypoxia appeared to be a fundamental causative factor in the production 
of HAPO. 
2.2 Observations by Other Workers 
The clinical observations mentioned above have not been added to substantially dur- 
ing the two decades that have passed since they were described, despite several 
reports of HAPO by authors around the world. However, views have been express- 
ed regarding the usefulness of various therapeutic measures and also on the funda- 
Table 1.  Incidence of  high altitude pulmonary oedema 
Author Region Incidence 
Menon1 Ladakh Himalayas 0.57% 
Singh and Roy4 Ladakh Himalayas 2.3-15.5% 
Hul tgrens Peru 0.4% 
Houston6 Kenya 0.44% 
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mental cause of HAPO. The following paragraphs discuss some of the observations 
made by other workers with a view to re-evaluate the earlier findings1 in the light of 
newer knowledge. 
2.2.1 Incidence of HAPO 
The incidence of HAPO as reported by various workers is shown in Table 1. 
The discrepency between the findings of Singh & Roy4 and the remaining authors 
is difficult to explain, but there is no doubt that the incidence is much lower than 15 
per cent and is definitely less than 1 per cent. Recently Adya (personal communica- 
tion, 1984) reporting from the Ladakh Himalayas has given the figure of 0.24 per cent 
amongst all inductees by air, and 0.13 per cent amongst fresh inductees by air, and 
0.3 per cent amongst re-inductees during the year 1983. 
2.2.2 Therapy of HAPO 
Evacuation to lower altitude and administration of oxygen have been accepted as the 
most important aspects of therapy. As far as troops at high altitude are concerned, 
evacuation to an altitude below 11,200 feet (3,413.7 m) (the location of the hospital) 
has not been found necessary as all patients of HAPO recovered at  this altitude 
with adequate therapy. Besides, since the aim of deploying troops for long periods 
at high altitude is to defend the outposts, evacuation of the individual after recovery 
to the plains is likely to affect morale. Mountaineers on the other hand have laid 
stress upon evacuation to a lower altitude as oxygen alone is reportedly ineffective. 
This is obviously because of the greater heights at which mountaineering parties 
operate, At 11,200 feet (3,413.7 m) there is no doubt about the efficacy of oxygen 
alone in 34 per cent of patients. 
Singh7 has advocated the use of the quick-acting diuretic furosemide, 40-80 mg 
intravenously in the management of HAPO. Recently doubts have been expressed 
regarding the usefulness of diuretics. Hultgrene is of the opinion that there is insu- 
fficient evidence from appropriately conducted clinical studies that furosemide is 
indicated and warned that in severe cases of HAPO (with a low cardiac output, 
haemoconcentration, and shock) furosemide is more likely to aggravate hypotension. 
Marticorena & Hultgreng evaluated their therapeutic measures and compared 
the treatment of 20 co~~trols on conventional therapy (including bed rest, and conti- 
nuous administration of oxygen) with 16 patients on bed rest alone (without oxygen 
or other therapy). No treatment failures occurred in either group. They concluded 
that HAPO of mild to moderate severity can be treated successfully with bed rest 
alone, without the administration of oxygen, and without moving the patient to a lower 
altitude. Oxygen therapy was considered slightly more effective as relief of symptoms 
was rapid. It is of interest to note that all the patients in the study were children" 
between three years and 19 years (mean age 9.8 years) and were almost all permanent 
residents of high altitude who had gone to the plains for a short sojourn and developed 
HAPO on coming back to high altitude. The situation in India is rather different 
both as regards age and residence at high altitude and it would be illogical to apply 
Marticorena & Hultgren's findings to our situation. 
The clinical details of the 101 cases of HAPO reported by the author2 have been 
re-examined in the light of the observations of Marticorena & Hultgren9. The 
treatment afforded to the 100 cases who reached hospital alive are given in Table 2. 
I t  was found that all the four deaths occurred early in the series before experience 
had been gained; there was no death amongst 94 consecutively treated cases-all 
treatment schedules being successful. The clinical data of 41 consecutive patients 
treated during the latter part of the study were reviewed and grading of severity of 
pulmonary oedema done as described by Marticorena & Hultgren i.e., based upon 
clinical symptoms, signs, radiological findings, and heart and respiratory rates, (see 
Appendix for criteria used). The grading and results of therapy in these 41 patients 
are given in Table 3. 
23 of the 41 patients (56 per cent) improved on bed rest with oxygen therapy 
alone, irrespective of the severity of pulmonary oedema. Even amongst patients with 
severe pulmonary oedema 12 out of 20 patients (60 per cent) needed no other therapy 
apart from oxygen. Lung signs cleared up in 2.9 days. Addition of morphine, 
digoxin or diuretics (Inj mersalyl/chlorotheazide) did not appreciably shorten the 
duration of persistence of lung signs. D~uretics were given to only 5 patients (12 per 
cent). Lung clearance took 4-5 days in severe cases. Although it cannot be inferred 
from this that diuretic therapy delayed recovery, there is no doubt that it did not 
hasten it in these particular patients. Certain unpublished observations by Dutta are 
pertinent in this connection. In 1972 Dutta (at Ladakh), treated 25 consecutive 
Table 2. Treatment regimes of 101 patients of HAPO 
Bed rest Oxygen Digoxin Morphia Diuretics Antibiotics No. of patients Deaths 
+ + - - - - 30 - 
+ + - - - + 3 2 
+ + + - - - 8 - 
f + + + 3 - - - 
+ + + + - - 6 - 
+ + + + + 2 - - 
+ + + + + - 1 - 
+ + + + + + 23 1 
4- + - - + + 1 - 
-t + + + 5 - - 
+ + + + + 18 - - 
Total : 101 4 
- - -- 
No. of patients treated with diuretics : 48 
No. of patients treated withoutdiuretics : 52 
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Table 3. Response to therapy of various grades of HAPO 
Severity of HAPO 
Treatment Grade 1 Grade 2 Grade 3 Grade 4 N o  of 
(Mild) (Moderate) (Serious) (Severe) patients 
(a) Oxygen only - 3 ( 2 )  S(2 .6 )  12 (2.9) 23 
(b) Oxygen + Digoxin - l ( 3 )  4 ( 2 . 9 )  3 (3.7) 8 
(c) Oxygen + Digoxin 
+ Morphine - 2 (2) - 3 (2.7) 5 
(d) Oxygen + Digoxin 
+ Morphine 
-!- Diuretics - 1 (3) 2 (4) 2 (4 .5 )  5 
Total 7 14 20 41 
Note : (Figures in brackets indicate average number of days for clinical clearance of lungs) 
patients of HAPO with bed rest, oxygen inhalations and morphia, withoutadminis- 
tration of furosemide. He compared the results with 25 cases of 'similar' severity 
treated on 'accepted' lines with bed rest, morphia, atropine, furosemide. betametha- 
sone and aminophylline. He observed that there was no difference in the outcome- 
all patients recovered. These observations cast serious doubts about the need for 
even quick-acting furosemide in the treatment of HAPO (personal communication). 
This retrospective analysis of the clinical findings in the 1962-1964 series of 101 
cases of HAPO, if anything, confirms the impression that it would be incorrect to lay 
down a standard method of treatment for all cases. There are no satisfactory criteria 
for grading the severity of pulmonary oedema in a manner to assist prognostication of 
eventual result. Although Marticorena & Hultgren's method is useful, as it is based 
upon several clinical and radiological criteria, it does not still provide an adequate 
background against which to plan the treatment of the individual patient. As indi- 
cated in Table 3 a patient with grade 4 (severe) pulmonary oedema may respond to 
oxygen inhalations alone, whereas another with only grade 2 (moderate) pulmonary 
oedema may not. 
Marticorena & Hultgren's cases from Peru were almost all, residents of high 
altitude, whereas in India the population affected belong to the plains and undertake 
1-2 year spells of duty at high altitude and then return to the plains. This basic 
difference in permanent residence may explain the occasional need for supplemental 
drug therapy amongst Indians suffering from HAPO. 
2.2.3 Pathophysiology of HAPO 
On the basis of the study of 101 cases it has been suggested that myocardial failure is 
an important factor in the production of HAPO. This has been postulated because 
of certain observations elaborated in the original article1 that tend to support this 
view. Briefly, these consist of history of nocturnal dyspnoea in 59/100 patients, 
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considerable elevation of pulse rate preceding rise in respiratory rate, a distinct rise 
in B.P. with recovery, barium swallow studies in six patients suggesting pressure on 
the oesophagus during the acute phase, and response to rapid I.V. digitalization in 
patients not recovering with oxygen therapy alone (and even in the absence of oxygen 
therapy). 
Y# 
As against this there have been studies doubting the role of myocardial dysfunc- 
tion in the production of HAPO. Fred et al.lO, Hultgren et a18'11'12, and Roy et all8 
have produced evidence to suggest this is not so. They have recorded normal wedge 
and left atrial pressures. Increased pulmonary artery pressures have been recorded 
by Vogel et all4 and Kronenberg el all5. All these studies have been performed on a 
handful of subjects and no large scale study has been done perhaps because invasive 
studies, especially at high altitude, have inherent risks. 
The prevailing opinion amongst most authorities is that the myocardium is basi- 
cally sound, and the cause of HAPO has to be searched elsewhere. However, 
authorities are not unanimous on the subject. Alexander et all6 felt that a decrease 
in myocardial contractility at altitude could result from impairment of myocardial 
oxygenation secondary to failure of oxygen transport or a decrement in coronary 
arterial tension or both. Balasubramanian and c o - w ~ r k e r s ~ ~ * l ~  demonstrated left 
ventricular dysfunction at high altitude by serial estimation of systolic time intervals 
in a pilot study of 20 volunteers inducted by air. H ~ o n ' ~  in his B C Roy Memorial 
Oration reporting on his findings in 329 subjects taken by air to high altitude demons- 
trated by non-invasive methods 'positive evidence of left ventricular dysfunction-the 
stroke volume was decreased, cardiac output decreased despite tachycardia, and all 
parameters of myocardial contractility levels. The evidence in respect of these con- 
clusions is considered unequivocal'. 
Subsequently, Das20 working on volunteers in the Himalayas has reported evidence 
of improvement in all myocardial function parameters by non-invasive techniques 
following the administration of digoxin. 
These observations would tend to suggest that the role of left ventricular dysfunc- 
tion in the production of high altitude pulmonary oedema cannot be lightly brushed 
aside, and further studies would have to be done on patients of HAPO during the 
acute phase and again on recovery before LV failure can categorically be excluded. 
Recently, Milledgez1 has mentioned the various possible pathophysiologica~ 
changes in HAPO. He says 'The clinical picture is of left ventricular failure but 
although it is hard to rule out entirely, the evidence of catheter studies is that pulmo- 
nary wedge pressure18122 and (on the basis of one patient with a patent foramen ovale) 
left atrial pressure are normal (Fred et all0). In all cases however the pulmonary 
artery pressure is greatly increased. The various mechanisms suggested are not mutu- 
ally exclusive and include an increase in capillary permeability as a direct result of 
hypoxia, or via mediators whose concentrations are increased by hypoxia; a non- 
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uniform vasoconstriction resulting in torrential flow in less constricted areas, leading 
to oedema in these areases*24 and fluid leakage through the arterial walls proximal to 
the resistance vessels. There is some suggestive evidence for all these possibilities. 
F The association of proteinuria with acute mountain sickness supports the idea of 
increased permeability of blood vessels. The other two mechanisms would explain 
the highly non-uniform appearance of this form of pulmonary oedema as seen on 
chest radiographs and at necropsy, where some areas of the lungs are found to be 
perfectly normal some oedematous and some frankly haemorrhagic. In both lung 
and brain a primary derangement of the clotting mechanism must be considered as a 
possible underlying mechanism'. 
From the above observations by MilledgeZ1 it would seem that left ventricular 
failure is a possible, though very unlikely, cause of HAPO. This may perhaps be 
the correct scientific view. However in the same issue of Thorax, Dickinson presents 
an interesting paper entitled 'Altitude related deaths in 7 trekkers in the Himalayas'. 
These are undoubtedly selected cases-all severely ill or dead on arrival at the hospital 
at Khatmandu. All these patients had pulmonary oedema on necropsy. A note- 
worthy feature of the therapy given to these patients was the exhibition of penicillin/ 
ampicillin, betamethasone, furosemide, mannitol and diamox to almost all the 
patients. Morphia given to one patient reportedly produced temporary relief from 
dyspnoea. Digoxin was administered intramuscularly to an individual, the dose not 
being specified. To a proponent of digoxin therapy for severe and unresponsive 
cases of HAPO and to one who has repeatedly observed the efficacy of both digoxin 
and morphia (like the present author), Dickinson's unfortunate series seems to vindi- 
cate the role of digoxin. One cannot help wondering if adecyse digitalization 
would not have reversed the downhill progress as it has done Jb: other equally ill 
patients in the author's series of 101 cases. This is downright speculation, but one 
based on close clinical observation. Perhaps, after all, left ventricular failure does 
play a role in the pathophysiology of HAPO. Until this is disproved, it may be 
prudent to administer digoxin to all seriously ill patients of HAPO not responding to 
oxygen inhalations and morphia. 
3. Conclusion 
This re-appraisal of a report of 101 cases of HAPO originally published in 1965 
suggests that the clinical pattern of the disease remains the same over the past two 
decades; the benefits of diuretic therapy in HAPO are doubtful; and the pathophy- 
siology of the disease is still unclear despite intensive study by workers all over the 
world. It is felt that the role of digoxin and morphia in the treatment of HAPO 
needs re-appraisal, and LV function in HAPO also needs to be studied. 
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Appendix 
Severity Classification of H A P 0  
(Modified from Marticorena & Hultgrens) 
(a) (b) (c) 
Grade Clinical symptoms Heart Resp X-ray find~ngs 
and signs rate rate 
I Minor symptoms dyspnoca 110 20 Minimal opacities, 
(Mild) on mild exertion less than 114 of 1 
lung 
I1 Weakness, fatigue, headache, 110-120 20-30 Opacities 112 of 1 
(Moderate) cough, dyspnoea at  rest lung 
III Severe dyspnoea, headache, 121-140 
(Serious) weakness, nausea, cough, 
wheezing cyanosis 
IV Clouded consciousness, 
(Severe) stupor, coma, unable to  
stand, weakness bubbling 140 
rales, copious sputum, 
usually bloody severe 
31-40 Opacities involving 
at  least 112 of each 
lung or unilateral 






Note : Overall grading is done by addition of grades of (a) and (c) with the average grading of 
heart rate and respiratory rate (b). 
